lung cancer
Read the September edition of Pharmafocus online now!
September 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, brexit, lung cancer, medicinal cannabis, pharma
The latest monthly edition of Pharmafocus, the September issue, is available to read for free online now!With a new Prime …
BMS unveils strong five-year efficacy data for Opdivo in lung cancer
September 11, 2019Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma
Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …
MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland
September 10, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma
MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …
Lilly’s LOXO-292 shrinks tumours in lung cancer trial
September 9, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma
Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …
AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer
September 9, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …
Roche celebrates European approval of Tecentriq combo in first-line lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq
Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …
Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma
Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …
AZ’s Tagrisso secures China approval in first-line advanced lung cancer
September 4, 2019Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma
AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …
AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer
August 21, 2019Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …
Roche’s cancer drug Rozlytrek scores double approval from FDA
August 16, 2019Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology
The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …
AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial
August 9, 2019Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma
AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …
Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund
August 8, 2019Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma
MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …
Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population
August 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma
German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) …
Roche’s Tecentriq combo recommended in Europe for non-small cell lung cancer
July 29, 2019Sales and Marketing Cancer, NSCLC, Roche, lung cancer, pharma, tecentriq
Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was …
BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer
July 25, 2019Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
